Literature DB >> 8352670

Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin.

R B Stricker1, B J Kwiatkowska, J A Habis, D D Kiprov.   

Abstract

Myasthenic crisis is a potentially life-threatening complication of myasthenia gravis that requires aggressive therapy. We describe four patients in whom myasthenic crisis developed and who failed to respond to initial treatment with intravenous gamma-globulin. All four patients subsequently responded to intensive plasma exchange. Based on our experience, plasmapheresis appears to be superior to intravenous gamma-globulin for the treatment of myasthenic crisis in certain patients. Prognostic factors that determine the effectiveness of intravenous gamma-globulin vs plasmapheresis in these patients merit further investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8352670     DOI: 10.1001/archneur.1993.00540080046012

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

1.  Myasthenic crisis.

Authors:  Linda C Wendell; Joshua M Levine
Journal:  Neurohospitalist       Date:  2011-01

Review 2.  Intravenous immunoglobulin treatment in neurological diseases.

Authors:  A Otten; M Vermeulen; P M Bossuyt; A Otten
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

3.  Comparison of IVIg and PLEX in patients with myasthenia gravis.

Authors:  D Barth; M Nabavi Nouri; E Ng; P Nwe; V Bril
Journal:  Neurology       Date:  2011-05-11       Impact factor: 9.910

4.  An Update on Myasthenic Crisis.

Authors:  Shafiuddin Ahmed; Jawad F Kirmani; Nazli Janjua; Ammar Alkawi; Ismail Khatri; Abutaher M Yahia; Nizar Souyah; Adnan I Qureshi
Journal:  Curr Treat Options Neurol       Date:  2005-03       Impact factor: 3.598

5.  Myasthenic Crisis.

Authors:  Jawad F. Kirmani; Abutaher M. Yahia; Adnan I. Qureshi
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

6.  Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.

Authors:  Vern C Juel; Janice M Massey
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

7.  Myasthenia Gravis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.972

Review 8.  Myasthenia gravis.

Authors:  Vern C Juel; Janice M Massey
Journal:  Orphanet J Rare Dis       Date:  2007-11-06       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.